Trump said he confronted global threats others ignored.

惠譽：上調2027年石油和2026-2027年TTF天然氣價格預期。

Novo Nordisk's CEO said the company must do more to rebuild investor trust as flagship drugs including Ozempic and Wegovy face patent expiries in the US and Europe over the next decade. He warned that overpromising and under-delivering quickly erodes confidence and that investors want clarity on the company's next steps. Shares fell on Monday after an investor day disappointed with limited detail on the turnaround plan. Ozempic and Wegovy account for roughly three-quarters of sales. Novo Nordisk has pledged to launch more than five major drugs by 2030 and to add over $23 bln in incremental sales by 2035; analysts say those targets largely meet expectations. BMO Capital Markets said the company remains in a proof-of-performance phase and investors need clearer visibility on next-generation drugs and likely market uptake to restore confidence.